Source: Eur Respir J 2001; 17: 295-301
Disease area: Interstitial lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jones A.M., Dodd M.E., Webb A.K.. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001; 17: 295-301

Member's Comments

No comment yet.

Related content which might interest you: Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Source: Eur Respir J 2004; 23: 851-856 Year: 2004 Burkholderia cepacia complex infection in Czech patients with cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Cystic fibrosis: the problem with B. cepacia and more Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Cystic fibrosis patients and families support cross-infection measures Source: Eur Respir J 2004; 24: 449-452 Year: 2004 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008 Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions Source: Eur Respir J 2003; 22: 542-550 Year: 2003 Achromobacter (A.) xylosoxidans in cystic fibrosis: prevalence and clinical relevance Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 The clinical impact of pseudomonas aeruginosa eradication in bronchiectasis in a Dutch center of expertise Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018 Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Source: Eur Respir J 2005; 25: 474-481 Year: 2005 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Phenotypic assessment of potential Burkholderia cepacia virulence associated determinants Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003 Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients Source: Eur Respir J 2001; 17: 36-38 Year: 2001 Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis Source: Eur Respir J 2014; 43: 900-903 Year: 2014 The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018 Year: 2019 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Enterobacteriaceae and Pseudomonas aeruginosa in community-acquired pneumonia: the reality after a decade of uncertainty? Source: Eur Respir J 2010; 35: 473-474 Year: 2010 Pseudomonas aeruginosa transmission is infrequent in New Zealand cystic fibrosis clinics Source: Eur Respir J 2008; 32: 1583-1590 Year: 2008 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021